Keyphrases
Farnesylthiosalicylic Acid
100%
RAS Inhibitors
100%
Human Tumor Cells
100%
S-trans
100%
PANC-1
40%
Gemcitabine
40%
Cytotoxic Drugs
30%
Acid Treatment
20%
Tumor
20%
Fibroblasts
20%
Tumor Cells
20%
Doxorubicin
20%
Anchorage
20%
Oncogenic Ras
20%
SW480 Cells
20%
Acid Activation
10%
Drug Resistance
10%
Growth Inhibition
10%
Epithelial Cells
10%
Opposite Effects
10%
Synergistic Effect
10%
Colon Cancer Cells
10%
Esters
10%
Survival Rate
10%
Ras Isoforms
10%
Tumor Growth
10%
Anti-apoptotic
10%
Cell Transformation
10%
Sequence Specificity
10%
Fold Increase
10%
Therapeutic Potential
10%
Cell Tumor
10%
Carboxymethylation
10%
Tumor Inhibition
10%
HEC-RAS
10%
Pancreatic Cancer Cells
10%
Anticancer Agents
10%
Induced Growth
10%
SW480
10%
Epithelial Origin
10%
EJ Cells
10%
Medicine and Dentistry
Tumor Cell
100%
Ras Signaling
100%
Salirasib
100%
Gemcitabine
40%
Cytotoxic Agent
30%
Tumor Progression
20%
Cancer Cell
20%
Neoplasm
20%
Carcinogenesis
20%
Doxorubicin
20%
Anchorage
20%
Fibroblast
20%
Survival Rate
10%
Pancreas Cancer
10%
Epithelial Cell
10%
Growth Inhibition
10%
Drug Resistance
10%
Colon Carcinoma
10%
Cell Transformation
10%
Antiapoptotic
10%
Anticancer Drug
10%
Biochemistry, Genetics and Molecular Biology
Gemcitabine
100%
Cancer Cell
50%
Carcinogenesis
50%
Tumor Progression
50%
Fibroblast
50%
Doxorubicin
50%
Drug Resistance
25%
Isoform
25%
Colon
25%
Anticancer
25%
Growth Inhibition
25%
Cell Transformation
25%
Survival Rate
25%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Salirasib
100%
Gemcitabine
40%
Cytotoxic Agent
30%
Tumor Growth
20%
Carcinogenesis
20%
Doxorubicin
20%
Drug Resistance
10%
Antiapoptotic
10%
Survival Rate
10%
Colon Carcinoma
10%
Pancreas Cancer
10%
Anticancer Drug
10%